FDA pushes back decisions on AbbVie's Rinvoq sNDAs to further review a failed Pfizer trial
Safety questions related to the lucrative class of medicines known as JAK inhibitors are continuing to slow the push to expand their labels.
AbbVie on …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
